Table 1.

Key Endpoints at Wk 52

EndpointsSirukumab 50 mg q4wSirukumab 100 mg q2w
Placebo toCombinedPlacebo toCombined
50 mg q4w (n=124)50 mg q4w (n=235)50 mg q4w (n=359)100 mg q2w (n=123)100 mg q2w (n=241)100 mg q2w (n=364)
ACR20 response, n (%)68 (54.8)127 (54.0)195 (54.3)71 (57.7)145 (60.2)216 (59.3)
ACR50 response, n (%)41 (33.1)74 (31.5)115 (32.0)38 (30.9)77 (32.0)115 (31.6)
HAQ-DI change from baseline, mean (SD)-0.30 (0.55)-0.39 (0.58)-0.36 (0.57)-0.43 (0.51)-0.43 (0.60)-0.43 (0.57)
DAS28 (CRP) <2.6, n (%)36 (29.0)63 (26.8)99 (27.6)42 (34.1)71 (29.5)113 (31.0)
SF-36 summary scores
PCS change from baseline, mean (SD)4.47 (7.70)6.33 (7.23)5.69 (7.44)5.45 (7.22)5.98 (7.25)5.80 (7.24)
MCS change from baseline, mean (SD)3.64 (8.48)5.19 (10.84)4.65 (10.10)5.60 (10.62)4.46 (10.45)4.85 (10.51)